Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer Journal Article
| Authors: | Dagogo-Jack, I.; Shaw, A. T.; Riely, G. J. |
| Article Title: | Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer |
| Abstract: | In the 9 years since the initial discovery of anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC), there has been tremendous progress, culminating in an ever-expanding repertoire of agents that have activity in this disease. This review article provides an overview of currently approved ALK inhibitors, other ALK inhibitors in development, and commonly described mechanisms of resistance to ALK inhibitors. We also discuss emerging controversies in treatment of patients with ALK-positive lung cancer, including the choice of first-line ALK inhibitor and the role of tyrosine kinase inhibitors in the treatment of central nervous system metastases. © 2017 American Society for Clinical Pharmacology and Therapeutics |
| Keywords: | drug approval; cancer patient; lung cancer; cancer therapy; cancer resistance; protein tyrosine kinase inhibitor; gene rearrangement; heat shock protein 90 inhibitor; anaplastic lymphoma kinase; central nervous system metastasis; clinical trial (topic); crizotinib; cancer prognosis; human; priority journal; article; ceritinib; alectinib; anaplastic lymphoma kinase inhibitor; brigatinib; entrectinib; lorlatinib; ensartinib; anaplastic lymphoma kinase positive lung cancer |
| Journal Title: | Clinical Pharmacology & Therapeutics |
| Volume: | 101 |
| Issue: | 5 |
| ISSN: | 0009-9236 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2017-05-01 |
| Start Page: | 625 |
| End Page: | 633 |
| Language: | English |
| DOI: | 10.1002/cpt.653 |
| PUBMED: | 28182271 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 June 2017 -- Source: Scopus |
